View in EDS HTML Full Text PDF Full Text

Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial.

Saved in:
Bibliographic Details
Title: Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial.
Authors: Scheck, Magdalena K.1 (AUTHOR), Goetze, Thorsten O.2 (AUTHOR), Ettrich, Thomas J.3 (AUTHOR), Schmalenberg, Harald4 (AUTHOR), Clemens, Michael5 (AUTHOR), Mahlberg, Rolf6 (AUTHOR), Heeg, Steffen7 (AUTHOR), Kanzler, Stephan8 (AUTHOR), Hapke, Gunnar9 (AUTHOR), Thuss-Patience, Peter10 (AUTHOR), Kestler, Angelika3 (AUTHOR), Treschl, Anne4 (AUTHOR), Heidel, Stefan6 (AUTHOR), Schiemer, Moritz7,11 (AUTHOR), Sookthai, Disorn12 (AUTHOR), Junge, Sabine12 (AUTHOR), Pauligk, Claudia12 (AUTHOR), Al-Batran, Salah-Eddin2 (AUTHOR), Lorenzen, Sylvie1 (AUTHOR)
Source: Oncology Research & Treatment. 2024, Vol. 47 Issue 11, p549-560. 12p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:22965270
DOI:10.1159/000541174